Literature DB >> 33594934

Anal cancer screening among women with HIV: provider experiences and system-level challenges.

Robin T Higashi1,2, Serena A Rodriguez1, Andrea C Betts3, Jasmin A Tiro1,2, Amneris E Luque1,4, Rachel Rivera5, Arti Barnes1,2.   

Abstract

Women living with HIV (WLWH) are at increased risk of anal cancer compared to women without HIV, often due to persistent human papillomavirus (HPV) infections. This paper describes current practices and challenges conducting anal cancer screening for WLWH at an urban integrated safety-net system and a non-profit community-based HIV clinic. We conducted 25 semi-structured interviews with clinical and administrative stakeholders to assess knowledge, clinic practices and procedures, and experiences with anal cancer screening. Interview transcripts and fieldnotes were thematically analyzed using an iterative deductive and inductive coding scheme. Findings were organized by the Consolidated Framework for Implementation Research (CFIR) domains and constructs. Provider-level barriers to conducting anal cancer screening included limited knowledge of guidelines. System-level barriers included: structural characteristics such as lack of coordination between clinics to discern provider roles and responsibilities; and limitations in available resources such as configuration of electronic health records and infrastructure to manage referrals of abnormal anal Pap results. We conclude that anal cancer screening and follow-up for WLWH requires organization and coordination between multiple care teams, updated clinical information systems to facilitate communication and support anal Pap ordering and result documentation, and infrastructure that includes policies and protocols for management of abnormal results.Trial registration: ClinicalTrials.gov identifier: NCT02135419.

Entities:  

Keywords:  Human papillomavirus (HPV); Papanicolaou (Pap) test; dysplasia; qualitative; risk perception; safety-net

Mesh:

Year:  2021        PMID: 33594934      PMCID: PMC8368076          DOI: 10.1080/09540121.2021.1883512

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  35 in total

Review 1.  Interfaces across the cancer continuum offer opportunities to improve the process of care.

Authors:  Stephen H Taplin; Steve Clauser; Anne B Rodgers; Erica Breslau; Daniel Rayson
Journal:  J Natl Cancer Inst Monogr       Date:  2010

2.  Anal Cancer Risk Among People With HIV Infection in the United States.

Authors:  Vivian Colón-López; Meredith S Shiels; Mark Machin; Ana P Ortiz; Howard Strickler; Philip E Castle; Ruth M Pfeiffer; Eric A Engels
Journal:  J Clin Oncol       Date:  2017-11-15       Impact factor: 44.544

3.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

Review 4.  Screening for Anal Cancer in Women.

Authors:  Anna-Barbara Moscicki; Teresa M Darragh; J Michael Berry-Lawhorn; Jennifer M Roberts; Michelle J Khan; Lori A Boardman; Elizabeth Chiao; Mark H Einstein; Stephen E Goldstone; Naomi Jay; Wendy M Likes; Elizabeth A Stier; Mark L Welton; Dorothy J Wiley; Joel M Palefsky
Journal:  J Low Genit Tract Dis       Date:  2015-07       Impact factor: 1.925

5.  Screening for anal cancer precursors among patients living with HIV in the absence of national guidelines: practitioners' perspectives.

Authors:  Alexis M Koskan; Stephanie A Brennhofer; Deborah L Helitzer
Journal:  Cancer Causes Control       Date:  2019-07-13       Impact factor: 2.506

6.  A cost-effectiveness analysis of anal cancer screening in HIV-positive women.

Authors:  Gweneth Bratton Lazenby; Elizabeth Ramsey Unal; Anne Lintzenich Andrews; Kit Simpson
Journal:  J Low Genit Tract Dis       Date:  2012-07       Impact factor: 1.925

7.  Sociodemographic Predictors of Anal Cancer Screening and Follow-up in Human Immunodeficiency Virus-Infected Individuals.

Authors:  Jessica S Wells; Marcia M Holstad; Deborah Watkins Bruner
Journal:  Cancer Nurs       Date:  2018 Sep/Oct       Impact factor: 2.592

Review 8.  Anal dysplasia in HIV-infected women: a commentary on the field.

Authors:  Catherine Godfrey; Cynthia S Firnhaber; Gypsyamber D'Souza; Isabelle Heard
Journal:  Int J STD AIDS       Date:  2015-11-04       Impact factor: 1.359

9.  Integrating evidence-based practices for increasing cancer screenings in safety net health systems: a multiple case study using the Consolidated Framework for Implementation Research.

Authors:  Shuting Liang; Michelle C Kegler; Megan Cotter; Phillips Emily; Derrick Beasley; April Hermstad; Rentonia Morton; Jeremy Martinez; Kara Riehman
Journal:  Implement Sci       Date:  2016-08-02       Impact factor: 7.327

10.  Barriers and facilitators to implementing cancer prevention clinical decision support in primary care: a qualitative study.

Authors:  Melissa L Harry; Anjali R Truitt; Daniel M Saman; Hillary A Henzler-Buckingham; Clayton I Allen; Kayla M Walton; Heidi L Ekstrom; Patrick J O'Connor; JoAnn M Sperl-Hillen; Joseph A Bianco; Thomas E Elliott
Journal:  BMC Health Serv Res       Date:  2019-07-31       Impact factor: 2.655

View more
  2 in total

1.  Genome-wide host methylation profiling of anal and cervical carcinoma.

Authors:  Erin M Siegel; Abidemi Ajidahun; Anders Berglund; Whitney Guerrero; Steven Eschrich; Ryan M Putney; Anthony Magliocco; Bridget Riggs; Kathryn Winter; Jeff P Simko; Jaffer A Ajani; Chandan Guha; Gordon S Okawara; Ibrahim Abdalla; Mark J Becker; Joseph F Pizzolato; Christopher H Crane; Kevin D Brown; David Shibata
Journal:  PLoS One       Date:  2021-12-09       Impact factor: 3.240

2.  Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County.

Authors:  Oluwadamilola Jolayemi; Laura M Bogart; Erik D Storholm; David Goodman-Meza; Elena Rosenberg-Carlson; Rebecca Cohen; Uyen Kao; Steve Shoptaw; Raphael J Landovitz
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.